Article
Absence of epidermal growth factor receptor gene mutations in patients with hormone refractory prostate cancer not responding to gefitinib.
The Prostate - 1 May 2007
Curigliano Giuseppe, Pelosi Giuseppe, De Pas Tommaso, Renne Giuseppe, De Cobelli Ottavio, Manzotti Michela, Spitaleri Gianluca, de Braud Filippo
Abstract excerpt
BACKGROUND: Mutations in the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR) gene in human cancers are associated with increased sensitivity to anilinoquinazoline EGFR inhibitors. To our knowledge no data have been reported on EGFR gene mutations in hormone refractory prostate cancer (HRPC). METHODS: Between March 2003 and December 2004, 23 patients with HRPC received 250 mg oral...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.